{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:42:51Z","timestamp":1759405371322,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.11.004","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T22:54:59Z","timestamp":1636844099000},"page":"7655-7660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine \u2013 United States, 2014\u20132019"],"prefix":"10.1016","volume":"39","author":[{"given":"Heather E.","family":"Reese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy A.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianca","family":"Vianzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Blain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadav","family":"Topaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Many","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bree","family":"Barbeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin P.","family":"Albertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charla","family":"DeBolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth F.","family":"Zaremski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Hannagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mbaeyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.11.004_b0005","unstructured":"Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm reports [Internet]. 2013; 62(2). Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6202a1.htm."},{"key":"10.1016\/j.vaccine.2021.11.004_b0010","unstructured":"Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2017. 2017."},{"key":"10.1016\/j.vaccine.2021.11.004_b0015","unstructured":"CDC. Meningococcal Disease Cases and Incidence by Serogroup and Age [Internet]. 2019. Available from: https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html."},{"issue":"2","key":"10.1016\/j.vaccine.2021.11.004_b0020","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00036-18","article-title":"Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine","volume":"9","author":"McNeil","year":"2018","journal-title":"MBio"},{"issue":"6","key":"10.1016\/j.vaccine.2021.11.004_b0025","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States","volume":"2","author":"Rajam","year":"2017","journal-title":"mSphere"},{"issue":"19","key":"10.1016\/j.vaccine.2021.11.004_b0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine \u2014 Advisory Committee on","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"10.1016\/j.vaccine.2021.11.004_b0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15585\/mmwr.mm6733a1","article-title":"National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13\u201317 Years \u2014 United States, 2018","volume":"67","author":"Walker","year":"2018","journal-title":"Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2021.11.004_b0040","unstructured":"CDC. No Title."},{"key":"10.1016\/j.vaccine.2021.11.004_b0045","unstructured":"CDC. Meningococcal Disease (Neisseria meningitidis) 2015 Case Definition [Internet]. [cited 2019 Nov 5]. Available from: https:\/\/wwwn.cdc.gov\/nndss\/conditions\/meningococcal-disease\/case-definition\/2015\/."},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.004_b0050","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: A portable approach to the identification of clones within populations of","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.vaccine.2021.11.004_b0055","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","article-title":"Population Structure and Capsular Switching of Invasive Neisseria meningitidis Isolates in the Pre-Meningococcal Conjugate Vaccine Era, United States, 2000\u20132005","volume":"201","author":"Harrison","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.11.004_b0060","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","article-title":"Antibody to Genome-Derived Neisserial Antigen 2132, a Neisseria meningitidis Candidate Vaccine, Confers Protection against Bacteremia in the Absence of Complement-Mediated Bactericidal Activity","volume":"188","author":"Welsch","year":"2003","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.11.004_b0065","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/IAI.05182-11","article-title":"Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding","volume":"79","author":"Giuntini","year":"2011","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.004_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00430-16","article-title":"Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci","volume":"24","author":"Giuntini","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.11.004_b0075","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.11.004_b0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment","volume":"17","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"33","key":"10.1016\/j.vaccine.2021.11.004_b0085","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1016\/j.vaccine.2017.06.020","article-title":"The Role of Anti-NHba Antibody in Bactericidal Activity Elicited by the Meningococcal Serogroup B Vaccine, MenB-4C","volume":"35","author":"Partridge","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.11.004_b0090","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative Serum Bactericidal Activity Bewteen Human Antibodies to Meningococcal Facor H Binding Protein and Neisserial Heparin Binding Antigen","volume":"29","author":"Vu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.004_b0095","unstructured":"Joint Committee on Vaccination and Immunisation. Minute of the meeting on 03 October 2018: Meningococcal Epidemiology. [Internet]. London, UK; 2018. Available from: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/229171862470."},{"issue":"31","key":"10.1016\/j.vaccine.2021.11.004_b0100","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","article-title":"Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch","volume":"37","author":"Deceuninck","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.004_b0105","unstructured":"Jones-Jack N, Rodgers L, MacNeil J, Mbaeyi S KK. Serogroup B meningococcal vaccine uptake among adolescents in six Immunization Information System Sentinel Sites \u2013 United States, 2015-2018. J Adolesc Heal."},{"key":"10.1016\/j.vaccine.2021.11.004_b0110","first-page":"1","article-title":"Meningococcal Serogroup B Disease in Vaccinated Children","author":"Soler-Garcia","year":"2019","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"39","key":"10.1016\/j.vaccine.2021.11.004_b0115","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.vaccine.2019.06.065","article-title":"Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type","volume":"37","author":"Packnett","year":"2019","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:21Z","timestamp":1759403241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21014389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":23,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21014389"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine \u2013 United States, 2014\u20132019","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}